Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 441

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 441
---
 agreements in effect as of December 31, 2024 are below:

| Drug molecules: up to the conditions and milestones of         |     | Amount |            |
|:---------------------------------------------------------------|:----|:-------|-----------:|
| Preclinical to IND filing                                      |     | $      |     30,000 |
| From entering phase 1 to before first commercial sale          |     |        |  2,120,000 |
| First commercial sale                                          |     |        |  1,600,000 |
| Net sales amount more than certain threshold in a year         |     |        | 14,000,000 |
| Subtotal                                                       |     | $      | 17,750,000 |
| Diagnostics technology: up to the conditions and milestones of |     |        |            |
| Before FDA approval                                            |     | $      |    146,417 |
|                                                                |     | $      | 17,896,417 |

F-32 APTORUM GROUP LIMITED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Stated in U.S. Dollars) 20. COMMITMENTS AND CONTINGENCIES (cont.) For the years ended December 31, 2024, 2023 and 2022, the Group incurred $61,123, $50,000 and $nil milestone payments under license agreements, respectively. For the years ended December 31, 2024, 2023 and 2022, the Group did not incur any royalties or research and development funding, respectively. Legal proceedings On December 16, 2024, the Group received a letter from Carey Olsen with a Summons with Notice dated September 3, 2024, taken out by Karen Cheung (a/k/a Wing TSZ Cheung) as plaintiff against, among others, the Group as defendant in the Supreme Court of the State of New York County of New York, in relation to an action to recover financial losses sustained by the plaintiff (the “Case”). The Case is at the very early stages of litigation and although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case. From time to time, the Group may be subject to certain legal proceedings, claims and disputes that arise in the ordinary course of business. Although the outcomes of these legal proceedings cannot be predicted, the Group does not believe these actions, in the aggregate, will have a material adverse impact on its financial position, results of